U.S. Markets open in 2 hrs 31 mins

Imagine Owning Second Sight Medical Products (NASDAQ:EYES) And Trying To Stomach The 80% Share Price Drop

Simply Wall St

It is a pleasure to report that the Second Sight Medical Products, Inc. (NASDAQ:EYES) is up 34% in the last quarter. But only the myopic could ignore the astounding decline over three years. Indeed, the share price is down a whopping 80% in the last three years. So it sure is nice to see a big of an improvement. The thing to think about is whether the business has really turned around.

See our latest analysis for Second Sight Medical Products

Second Sight Medical Products isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Over three years, Second Sight Medical Products grew revenue at 2.5% per year. That's not a very high growth rate considering it doesn't make profits. Nonetheless, it's fair to say the rapidly declining share price (down 41%, compound, over three years) suggests the market is very disappointed with this level of growth. While we're definitely wary of the stock, after that kind of performance, it could be an over-reaction. Of course, revenue growth is nice but generally speaking the lower the profits, the riskier the business - and this business isn't making steady profits.

You can see how revenue and earnings have changed over time in the image below, (click on the chart to see cashflow).

NasdaqCM:EYES Income Statement, April 17th 2019

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts

A Different Perspective

Second Sight Medical Products shareholders are down 38% for the year, but the broader market is up 8.2%. Of course the long term matters more than the short term, and even great stocks will sometimes have a poor year. However, the loss over the last year isn't as bad as the 41% per annum loss investors have suffered over the last three years. We'd need clear signs of growth in the underlying business before we could muster much enthusiasm for this one. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of Second Sight Medical Products by clicking this link.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.